A Photodynamic and Boron Neutron Capture Therapy Agent

LSU Reference: 0446


Description: Benign, water-soluble porphyrin-based compounds accumulate preferentially in cancerous cells, where they be activated by either of two modalities: 1) Photodynamic Therapy (PDT); or 2) Boron Neutron Capture Therapy (BNCT)

Download printable brochure here.

  • Photodynamic cancer therapy
  • Boron neutron capture cancer therapy
  • Macular degeneration of the eye treatment
  • Antibacterial agents
  • Antiviral/virucidal agents
  • Autoradiography Imaging
  • MRI contrast agent
  • X-ray radiography contrast agent

  • Low toxicity in unactivated form
  • Dual-mode use

Abstract: Boron neutron capture therapy (BNCT) is an oncology protocol consisting of the irradiation of 10B-rich tumors with low-energy neutrons, initiating a cascade of nuclear reaction products -- a 1.47 MeV a particle, a 0.84 MeV lithium ion (7Li3+), and a 0.48 MeV g-ray – that are highly damaging to tumor cells. Our new porphyrin-based compounds are water-soluble, preferentially deliver 10B to neoplastic tissue, and may also be used in a second, independent therapeutic protocol, photodynamic therapy (PDT), which generates highly-reactive singlet oxygen (1O2) and other cytotoxic species through irradiation of tissue-penetrating red light. Cellular uptake is excellent, “dark” toxicity is low and intracellular concentrations are moderate, making our compounds good candidates for advanced imaging techniques.